Trans-cinnamaldehyde improves memory impairment by blocking microglial activation through the destabilization of iNOS mRNA in mice challenged with lipopolysaccharide

Liqing Zhang, Zhangang Zhang, Yan Fu, Pin Yang, Zhenxia Qin, Yongjun Chen, Ying Xu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Microglia activation and neuroinflammation are critically involved in pathogenesis of neurodegenerative disorders. Patients with neurodegenerative disorders often suffer memory impairment and currently there is no effective treatment for inflammation-led memory impairment. Trans-cinnamaldehyde (TCA) isolated from medicinal herb Cinnamomum cassia has been shown to exhibit anti-inflammatory capability. However, the potential of TCA to be used to improve memory impairment under neuroinflammation has not been explored. Primary microglia stimulated by lipopolysaccharide (LPS) were used to evaluate the potential anti-neuroinflammatory effects of TCA by examining the production of nitric oxide (NO), expression of inducible nitric oxide synthase (iNOS), pro-inflammatory cytokines, and activation of MAPKs. A mouse model of LPS-induced memory impairment was established to assess the neuroprotective effects of TCA against memory deficit and synaptic plasticity inhibition by both behavioral tests and electrophysiological recordings. TCA pretreatment decreased LPS-induced morphological changes, NO production and IL-1β release in primary microglia. Decreased NO production was due to the accelerated degradation of iNOS mRNA in LPS-stimulated microglia through TCA's inhibitory effect on MEK1/2-ERK1/2 signaling pathway. TCA was able to reduce the levels of iNOS and phosphorylated ERK1/2 in hippocampus of mice challenged with LPS. Most importantly, TCA significantly lessened memory deficit and improved synaptic plasticity in LPS-challenged mice. This study demonstrates that TCA suppressed microglial activation by destabilizing iNOS mRNA, which leads to improved memory impairment in mice suffering neuroinflammation.

Original languageEnglish (US)
Pages (from-to)503-518
Number of pages16
JournalNeuropharmacology
Volume110
DOIs
StatePublished - Nov 1 2016

Fingerprint

Nitric Oxide Synthase Type II
Lipopolysaccharides
Messenger RNA
Microglia
Nitric Oxide
Neuronal Plasticity
Memory Disorders
Neurodegenerative Diseases
Cinnamomum aromaticum
cinnamic aldehyde
MAP Kinase Signaling System
Neuroprotective Agents
Medicinal Plants
Interleukin-1
Hippocampus
Anti-Inflammatory Agents
Cytokines
Inflammation

Keywords

  • MEK1/2-ERK1/2 signaling pathway
  • Memory impairment
  • Microglial activation
  • Neuroinflammation
  • Trans-cinnamaldehyde
  • iNOS mRNA stability

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Trans-cinnamaldehyde improves memory impairment by blocking microglial activation through the destabilization of iNOS mRNA in mice challenged with lipopolysaccharide. / Zhang, Liqing; Zhang, Zhangang; Fu, Yan; Yang, Pin; Qin, Zhenxia; Chen, Yongjun; Xu, Ying.

In: Neuropharmacology, Vol. 110, 01.11.2016, p. 503-518.

Research output: Contribution to journalArticle

Zhang, Liqing ; Zhang, Zhangang ; Fu, Yan ; Yang, Pin ; Qin, Zhenxia ; Chen, Yongjun ; Xu, Ying. / Trans-cinnamaldehyde improves memory impairment by blocking microglial activation through the destabilization of iNOS mRNA in mice challenged with lipopolysaccharide. In: Neuropharmacology. 2016 ; Vol. 110. pp. 503-518.
@article{2ebbe24ace7e4f4791f50b6ae58235d0,
title = "Trans-cinnamaldehyde improves memory impairment by blocking microglial activation through the destabilization of iNOS mRNA in mice challenged with lipopolysaccharide",
abstract = "Microglia activation and neuroinflammation are critically involved in pathogenesis of neurodegenerative disorders. Patients with neurodegenerative disorders often suffer memory impairment and currently there is no effective treatment for inflammation-led memory impairment. Trans-cinnamaldehyde (TCA) isolated from medicinal herb Cinnamomum cassia has been shown to exhibit anti-inflammatory capability. However, the potential of TCA to be used to improve memory impairment under neuroinflammation has not been explored. Primary microglia stimulated by lipopolysaccharide (LPS) were used to evaluate the potential anti-neuroinflammatory effects of TCA by examining the production of nitric oxide (NO), expression of inducible nitric oxide synthase (iNOS), pro-inflammatory cytokines, and activation of MAPKs. A mouse model of LPS-induced memory impairment was established to assess the neuroprotective effects of TCA against memory deficit and synaptic plasticity inhibition by both behavioral tests and electrophysiological recordings. TCA pretreatment decreased LPS-induced morphological changes, NO production and IL-1β release in primary microglia. Decreased NO production was due to the accelerated degradation of iNOS mRNA in LPS-stimulated microglia through TCA's inhibitory effect on MEK1/2-ERK1/2 signaling pathway. TCA was able to reduce the levels of iNOS and phosphorylated ERK1/2 in hippocampus of mice challenged with LPS. Most importantly, TCA significantly lessened memory deficit and improved synaptic plasticity in LPS-challenged mice. This study demonstrates that TCA suppressed microglial activation by destabilizing iNOS mRNA, which leads to improved memory impairment in mice suffering neuroinflammation.",
keywords = "MEK1/2-ERK1/2 signaling pathway, Memory impairment, Microglial activation, Neuroinflammation, Trans-cinnamaldehyde, iNOS mRNA stability",
author = "Liqing Zhang and Zhangang Zhang and Yan Fu and Pin Yang and Zhenxia Qin and Yongjun Chen and Ying Xu",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.neuropharm.2016.08.013",
language = "English (US)",
volume = "110",
pages = "503--518",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Trans-cinnamaldehyde improves memory impairment by blocking microglial activation through the destabilization of iNOS mRNA in mice challenged with lipopolysaccharide

AU - Zhang, Liqing

AU - Zhang, Zhangang

AU - Fu, Yan

AU - Yang, Pin

AU - Qin, Zhenxia

AU - Chen, Yongjun

AU - Xu, Ying

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Microglia activation and neuroinflammation are critically involved in pathogenesis of neurodegenerative disorders. Patients with neurodegenerative disorders often suffer memory impairment and currently there is no effective treatment for inflammation-led memory impairment. Trans-cinnamaldehyde (TCA) isolated from medicinal herb Cinnamomum cassia has been shown to exhibit anti-inflammatory capability. However, the potential of TCA to be used to improve memory impairment under neuroinflammation has not been explored. Primary microglia stimulated by lipopolysaccharide (LPS) were used to evaluate the potential anti-neuroinflammatory effects of TCA by examining the production of nitric oxide (NO), expression of inducible nitric oxide synthase (iNOS), pro-inflammatory cytokines, and activation of MAPKs. A mouse model of LPS-induced memory impairment was established to assess the neuroprotective effects of TCA against memory deficit and synaptic plasticity inhibition by both behavioral tests and electrophysiological recordings. TCA pretreatment decreased LPS-induced morphological changes, NO production and IL-1β release in primary microglia. Decreased NO production was due to the accelerated degradation of iNOS mRNA in LPS-stimulated microglia through TCA's inhibitory effect on MEK1/2-ERK1/2 signaling pathway. TCA was able to reduce the levels of iNOS and phosphorylated ERK1/2 in hippocampus of mice challenged with LPS. Most importantly, TCA significantly lessened memory deficit and improved synaptic plasticity in LPS-challenged mice. This study demonstrates that TCA suppressed microglial activation by destabilizing iNOS mRNA, which leads to improved memory impairment in mice suffering neuroinflammation.

AB - Microglia activation and neuroinflammation are critically involved in pathogenesis of neurodegenerative disorders. Patients with neurodegenerative disorders often suffer memory impairment and currently there is no effective treatment for inflammation-led memory impairment. Trans-cinnamaldehyde (TCA) isolated from medicinal herb Cinnamomum cassia has been shown to exhibit anti-inflammatory capability. However, the potential of TCA to be used to improve memory impairment under neuroinflammation has not been explored. Primary microglia stimulated by lipopolysaccharide (LPS) were used to evaluate the potential anti-neuroinflammatory effects of TCA by examining the production of nitric oxide (NO), expression of inducible nitric oxide synthase (iNOS), pro-inflammatory cytokines, and activation of MAPKs. A mouse model of LPS-induced memory impairment was established to assess the neuroprotective effects of TCA against memory deficit and synaptic plasticity inhibition by both behavioral tests and electrophysiological recordings. TCA pretreatment decreased LPS-induced morphological changes, NO production and IL-1β release in primary microglia. Decreased NO production was due to the accelerated degradation of iNOS mRNA in LPS-stimulated microglia through TCA's inhibitory effect on MEK1/2-ERK1/2 signaling pathway. TCA was able to reduce the levels of iNOS and phosphorylated ERK1/2 in hippocampus of mice challenged with LPS. Most importantly, TCA significantly lessened memory deficit and improved synaptic plasticity in LPS-challenged mice. This study demonstrates that TCA suppressed microglial activation by destabilizing iNOS mRNA, which leads to improved memory impairment in mice suffering neuroinflammation.

KW - MEK1/2-ERK1/2 signaling pathway

KW - Memory impairment

KW - Microglial activation

KW - Neuroinflammation

KW - Trans-cinnamaldehyde

KW - iNOS mRNA stability

UR - http://www.scopus.com/inward/record.url?scp=84983650267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983650267&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2016.08.013

DO - 10.1016/j.neuropharm.2016.08.013

M3 - Article

VL - 110

SP - 503

EP - 518

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -